Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
1.520
-0.035 (-2.25%)
Mar 31, 2025, 2:23 PM EDT - Market open
Adagene Employees
Adagene had 174 employees as of December 31, 2023. The number of employees decreased by 74 or -29.84% compared to the previous year.
Employees
174
Change (1Y)
-74
Growth (1Y)
-29.84%
Revenue / Employee
$593
Profits / Employee
-$192,093
Market Cap
71.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | 198 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADAG News
- 7 days ago - Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 18 days ago - Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewsWire
- 25 days ago - Adagene to Present at Leerink's Global Healthcare Conference 2025 - GlobeNewsWire
- 4 weeks ago - Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewsWire
- 2 months ago - CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso, - GlobeNewsWire
- 2 months ago - Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 5 months ago - Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 6 months ago - Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire